{"url": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069605/", "query": "oral chelation heart disease", "actual-search-type": "t", "expected-search-type": "t", "contents": "<?xml version=\"1.0\" encoding=\"utf-8\"?>\n<!DOCTYPE html PUBLIC \"-//W3C//DTD XHTML 1.0 Transitional//EN\" \"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd\">\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\">\n    \n    <head><meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n        <!-- AppResources meta begin -->\n        <script type=\"text/javascript\">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name=\"paf_template\" content=\"\" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name=\"ncbi_db\" content=\"pmc\" /><meta name=\"ncbi_pdid\" content=\"article\" /><meta name=\"ncbi_acc\" content=\"\" /><meta name=\"ncbi_domain\" content=\"nihpa\" /><meta name=\"ncbi_report\" content=\"record\" /><meta name=\"ncbi_type\" content=\"fulltext\" /><meta name=\"ncbi_objectid\" content=\"\" /><meta name=\"ncbi_pcid\" content=\"/articles/PMC4069605/\" /><meta name=\"ncbi_app\" content=\"pmc\" />\n        <!-- Logger end -->\n        \n        <title>EDTA Chelation Therapy Alone and in Combination with Oral High-Dose Multivitamins and Minerals for Coronary Disease: The Factorial Group Results of the Trial to Assess Chelation Therapy</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel=\"stylesheet\" href=\"/core/jig/1.14.8/css/jig.min.css\" /><script type=\"text/javascript\" src=\"/core/jig/1.14.8/js/jig.min.js\"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name=\"robots\" content=\"INDEX,NOFOLLOW,NOARCHIVE\" /><link rel=\"canonical\" href=\"/pmc/articles/PMC4069605/\" /><link rel=\"schema.DC\" href=\"http://purl.org/DC/elements/1.0/\" /><meta name=\"citation_journal_title\" content=\"American heart journal\" /><meta name=\"citation_title\" content=\"EDTA Chelation Therapy Alone and in Combination with Oral High-Dose Multivitamins and Minerals for Coronary Disease: The Factorial Group Results of the Trial to Assess Chelation Therapy\" /><meta name=\"citation_authors\" content=\"Gervasio A. Lamas, Robin Boineau, Christine Goertz, Daniel B. Mark, Yves Rosenberg, Mario Stylianou, Theodore Rozema, Richard L. Nahin, L. Terry Chappell, Lauren Lindblad, Eldrin F. Lewis, Jeanne Drisko, Kerry L. Lee, the TACT Investigators\" /><meta name=\"citation_date\" content=\"July 2014\" /><meta name=\"citation_issue\" content=\"1\" /><meta name=\"citation_volume\" content=\"168\" /><meta name=\"citation_firstpage\" content=\"37\" /><meta name=\"citation_doi\" content=\"10.1016/j.ahj.2014.02.012\" /><meta name=\"citation_abstract_html_url\" content=\"/pmc/articles/PMC4069605/?report=abstract\" /><meta name=\"citation_pmid\" content=\"24952858\" /><meta name=\"DC.Title\" content=\"EDTA Chelation Therapy Alone and in Combination with Oral High-Dose Multivitamins and Minerals for Coronary Disease: The Factorial Group Results of the Trial to Assess Chelation Therapy\" /><meta name=\"DC.Type\" content=\"Text\" /><meta name=\"DC.Publisher\" content=\"NIH Public Access\" /><meta name=\"DC.Contributor\" content=\"Gervasio A. Lamas\" /><meta name=\"DC.Contributor\" content=\"Robin Boineau\" /><meta name=\"DC.Contributor\" content=\"Christine Goertz\" /><meta name=\"DC.Contributor\" content=\"Daniel B. Mark\" /><meta name=\"DC.Contributor\" content=\"Yves Rosenberg\" /><meta name=\"DC.Contributor\" content=\"Mario Stylianou\" /><meta name=\"DC.Contributor\" content=\"Theodore Rozema\" /><meta name=\"DC.Contributor\" content=\"Richard L. Nahin\" /><meta name=\"DC.Contributor\" content=\"L. Terry Chappell\" /><meta name=\"DC.Contributor\" content=\"Lauren Lindblad\" /><meta name=\"DC.Contributor\" content=\"Eldrin F. Lewis\" /><meta name=\"DC.Contributor\" content=\"Jeanne Drisko\" /><meta name=\"DC.Contributor\" content=\"Kerry L. Lee\" /><meta name=\"DC.Contributor\" content=\"the TACT Investigators\" /><meta name=\"DC.Date\" content=\"2014 Jul\" /><meta name=\"DC.Identifier\" content=\"10.1016/j.ahj.2014.02.012\" /><meta name=\"DC.Language\" content=\"en\" /><meta property=\"og:title\" content=\"EDTA Chelation Therapy Alone and in Combination with Oral High-Dose Multivitamins and Minerals for Coronary Disease: The Factorial Group Results of the Trial to Assess Chelation Therapy\" /><meta property=\"og:type\" content=\"article\" /><meta property=\"og:description\" content=\"Disodium ethylene diamine tetraacetic acid (EDTA) reduced adverse cardiac outcomes in a factorial trial also testing oral vitamins.This report describes the intent-to-treat comparison of the 4 factorial groups overall and in patients with diabetes.Double-blind ...\" /><meta property=\"og:url\" content=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069605/\" /><meta property=\"og:site_name\" content=\"PubMed Central (PMC)\" /><meta property=\"og:image\" content=\"https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png\" /><meta name=\"twitter:card\" content=\"summary\" /><meta name=\"twitter:site\" content=\"@ncbi\" /><link rel=\"stylesheet\" href=\"/corehtml/pmc/css/3.6/pmc.min.css\" type=\"text/css\" /><link rel=\"stylesheet\" href=\"/corehtml/pmc/css/3.6/pmc_extras_prnt.min.css\" type=\"text/css\" media=\"print\" /><script type=\"text/javascript\" src=\"/corehtml/pmc/js/common.min.js\">//</script><script type=\"text/javascript\" src=\"/corehtml/pmc/js/NcbiTagServer.min.js\">//</script><meta name=\"citationexporter\" content=\"backend:'/pmc/utils/ctxp/'\" /><script type=\"text/javascript\" src=\"/corehtml/pmc/ctxp/jquery.citationexporter.js\">//</script><link rel=\"stylesheet\" href=\"/corehtml/pmc/ctxp/citationexporter.css\" type=\"text/css\" /><script type=\"text/javascript\" src=\"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js\"></script><script type=\"text/javascript\" src=\"/corehtml/pmc/js/large-obj-scrollbars.min.js\"></script><script type=\"text/javascript\">window.name=\"mainwindow\";</script><style type=\"text/css\">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}</style><style type=\"text/css\">.print-view{display:block}</style><style type=\"text/css\">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name=\"cited_in_systematic_reviews\" content=\"\" /><link rel=\"alternate\" type=\"application/epub+zip\" href=\"/pmc/articles/PMC4069605/epub/\" /><link rel=\"alternate\" type=\"application/pdf\" href=\"/pmc/articles/PMC4069605/pdf/nihms-583147.pdf\" />\n\n        <!-- Page meta end -->\n    <link rel=\"shortcut icon\" href=\"//www.ncbi.nlm.nih.gov/favicon.ico\" /><meta name=\"ncbi_phid\" content=\"F4FC57FD81E98D31000000000043003B\" /><link type=\"text/css\" rel=\"stylesheet\" href=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4120508/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css\" /><link type=\"text/css\" rel=\"stylesheet\" href=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/css/3411343/3882866/3929378.css\" media=\"print\" /></head>\n    <body class=\"article\">\n        <div class=\"grid\">\n            <div class=\"col twelve_col nomargin shadow\">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class=\"sysmessages\">\n                    <noscript>\n\t<p class=\"nojs\">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href=\"/guide/browsers/#enablejs\" title=\"Learn how to enable JavaScript\" target=\"_blank\">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class=\"wrap\">\n                    <div class=\"page\">\n                        <div class=\"top\">\n                            <div class=\"universal_header\" id=\"universal_header\"><ul class=\"inline_list jig-ncbimenu ui-ncbimenu resources_list\" id=\"navcontent\"><li class=\"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt\"><a class=\"ui-ncbimenu-link-first\" href=\"/\" role=\"banner\" title=\"NCBI Home\" id=\"ncbihome\" accesskey=\"1\"><span class=\"offscreen_noflow\">NCBI</span><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/28977\" class=\"ncbi_logo\" title=\"NCBI\" alt=\"NCBI Logo\" /></a></li><li class=\"offscreen_noflow ui-ncbimenu-item-skip access\"><a href=\"#maincontent\" title=\"Skip to the content\" tabindex=\"0\" accesskey=\"3\">Skip to main\n                        content</a></li><li class=\"offscreen_noflow ui-ncbimenu-item-skip access\"><a href=\"#navcontent\" title=\"Skip to the navigation\" tabindex=\"0\" accesskey=\"4\">Skip to\n                        navigation</a></li><li id=\"resource-menu\" class=\"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset\"><a class=\"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown\" href=\"/static/header_footer_ajax/submenu/#resources\">Resources</a></li><li id=\"all-howtos-menu\" class=\"topmenu ui-helper-reset ui-ncbimenu-item-first\"><a class=\"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown\" href=\"/static/header_footer_ajax/submenu/#howto\">How To</a></li><li class=\"offscreen_noflow ui-ncbimenu-item-skip access\"><a href=\"/guide/browsers/#accesskeys\" title=\"About My NCBI Accesskeys\" tabindex=\"0\" accesskey=\"0\">About NCBI Accesskeys</a></li></ul><div class=\"myncbi\"><span id=\"myncbiusername\" style=\"display:none\"><a href=\"/account/settings/\" id=\"mnu\" title=\"Edit account settings\"></a></span><a accesskey=\"2\" href=\"/myncbi/\" id=\"myncbi\" style=\"display:none\">My NCBI</a><a href=\"/account/\" id=\"sign_in\">Sign in to NCBI</a><a href=\"/account/signout/\" id=\"sign_out\" style=\"display:none\">Sign Out</a></div></div>\n                            <div class=\"header\">\n    <div class=\"res_logo\">\n  <h1 class=\"img_logo\"><a href=\"/pmc/\" class=\"pmc_logo offscreen\">PMC</a></h1>\n  <div class=\"NLMLogo\">\n    <a href=\"https://www.nlm.nih.gov/\" title=\"US National Library of Medicine\">US National Library of Medicine</a>\n    <br />\n    <a href=\"https://www.nih.gov/\" title=\"National Institutes of Health\">National Institutes of Health</a>\n  </div>\n</div>\n    <div class=\"search\"><form method=\"get\" action=\"/pmc/\"><div class=\"search_form\"><label for=\"database\" class=\"offscreen_noflow\">Search database</label><select id=\"database\"><optgroup label=\"Recent\"><option value=\"pmc\" selected=\"selected\" class=\"last\" data-ac_dict=\"pmc-search-autocomplete\">PMC</option></optgroup><optgroup label=\"All\"><option value=\"gquery\">All Databases</option><option value=\"assembly\">Assembly</option><option value=\"bioproject\">BioProject</option><option value=\"biosample\">BioSample</option><option value=\"biosystems\">BioSystems</option><option value=\"books\">Books</option><option value=\"clinvar\">ClinVar</option><option value=\"clone\">Clone</option><option value=\"cdd\">Conserved Domains</option><option value=\"gap\">dbGaP</option><option value=\"dbvar\">dbVar</option><option value=\"nucest\">EST</option><option value=\"gene\">Gene</option><option value=\"genome\">Genome</option><option value=\"gds\">GEO DataSets</option><option value=\"geoprofiles\">GEO Profiles</option><option value=\"nucgss\">GSS</option><option value=\"gtr\">GTR</option><option value=\"homologene\">HomoloGene</option><option value=\"medgen\">MedGen</option><option value=\"mesh\">MeSH</option><option value=\"ncbisearch\">NCBI Web Site</option><option value=\"nlmcatalog\">NLM Catalog</option><option value=\"nuccore\">Nucleotide</option><option value=\"omim\">OMIM</option><option value=\"pmc\" data-ac_dict=\"pmc-search-autocomplete\">PMC</option><option value=\"popset\">PopSet</option><option value=\"probe\">Probe</option><option value=\"protein\">Protein</option><option value=\"proteinclusters\">Protein Clusters</option><option value=\"pcassay\">PubChem BioAssay</option><option value=\"pccompound\">PubChem Compound</option><option value=\"pcsubstance\">PubChem Substance</option><option value=\"pubmed\">PubMed</option><option value=\"pubmedhealth\">PubMed Health</option><option value=\"snp\">SNP</option><option value=\"sparcle\">Sparcle</option><option value=\"sra\">SRA</option><option value=\"structure\">Structure</option><option value=\"taxonomy\">Taxonomy</option><option value=\"toolkit\">ToolKit</option><option value=\"toolkitall\">ToolKitAll</option><option value=\"toolkitbook\">ToolKitBook</option><option value=\"toolkitbookgh\">ToolKitBookgh</option><option value=\"unigene\">UniGene</option></optgroup></select><div class=\"nowrap\"><label for=\"term\" class=\"offscreen_noflow\" accesskey=\"/\">Search term</label><div class=\"nowrap\"><input type=\"text\" name=\"term\" id=\"term\" title=\"Search PMC. Use up and down arrows to choose an item from the autocomplete.\" value=\"\" class=\"jig-ncbiclearbutton jig-ncbiautocomplete\" data-jigconfig=\"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'\" autocomplete=\"off\" data-sbconfig=\"ds:'no',pjs:'no',afs:'yes'\" /></div><button id=\"search\" type=\"submit\" class=\"button_search nowrap\" cmd=\"go\">Search</button></div></div></form><ul class=\"searchlinks inline_list\"><li>\n                        <a href=\"/pmc/advanced/\">Advanced</a>\n                    </li><li>\n                        <a href=\"/pmc/journals/\">Journal list</a>\n                    </li><li class=\"help\">\n                        <a target=\"_blank\" href=\"/books/NBK3825/\">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id=\"Page\" label=\"headcontent\"/>-->\n                            \n                        </div>\n                        <div class=\"content\">\n                            <!-- site messages -->\n                            <div class=\"container\">\n    <div id=\"maincontent\" class=\"content eight_col col\">\n        <div class=\"navlink-box\">\n            <ul class=\"page-breadcrumbs inline_list small\"><li class=\"journal-list\"><a href=\"/pmc/journals/\" class=\"navlink\">Journal List</a></li><li class=\"article-entrez-filter\"><a href=\"/pmc/?term=hhs%20author%20manuscript[filter]\" class=\"navlink\">HHS Author Manuscripts</a></li><li class=\"accid\">PMC4069605</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class=\"pmc-page-banner whole_rhythm\"><div><img src=\"/corehtml/pmc/pmcgifs/logo-hhspa.png\" alt=\"Logo of nihpa\" usemap=\"#logo-imagemap\" /><map id=\"logo-imagemap\" name=\"logo-imagemap\"><area shape=\"rect\" coords=\"0,57,255,75\" alt=\"About Author manuscripts\" title=\"About Author manuscripts\" href=\"https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html\" ref=\"https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html\" /><area shape=\"rect\" coords=\"256,57,500,75\" alt=\"Submit a manuscript\" title=\"Submit a manuscript\" href=\"https://www.nihms.nih.gov/\" ref=\"reftype=publisher&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal\" target=\"pmc_ext\" /><area shape=\"rect\" coords=\"0,0,499,74\" alt=\"HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;\" title=\"HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;\" href=\"https://www.ncbi.nlm.nih.gov/pmc/about/public-access/\" ref=\"reftype=publisher&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal\" target=\"pmc_ext\" /></map></div> </div>\n        \n        <!--component id='MainPortlet' label='search-reference'/-->\n        \n        <!-- Book content -->\n        <div class=\"\">\n            \n        \n            \n            <div class=\"hide-overflow article lit-style content pmc-wm slang-all page-box\"><!--main-content--><div class=\"jig-ncbiinpagenav\" data-jigconfig=\"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'\"><div class=\"fm-sec half_rhythm no_top_margin\"><div class=\"fm-citation half_rhythm no_top_margin clearfix\"><div class=\"small\"><div class=\"inline_block eight_col va_top\"><div><span id=\"pmcmata\">Am Heart J</span>. Author manuscript; available in PMC 2015 Jul 1.</div><div></div><div>Published in final edited form as:</div><div style=\"margin-left:1em\"><div class=\"fm-vol-iss-date\"><a href=\"/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=24952858\" target=\"pmc_ext\" ref=\"reftype=publisher&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access&amp;rendering-type=normal\"><span class=\"cit\">Am Heart J. 2014 Jul; 168(1): 37\u201344.e5. </span></a></div><span class=\"fm-vol-iss-date\">Published online 2014 Apr 2. </span> <span class=\"doi\">doi:\u00a0 <a href=\"//dx.doi.org/10.1016%2Fj.ahj.2014.02.012\" target=\"pmc_ext\" ref=\"reftype=other&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal\">10.1016/j.ahj.2014.02.012</a></span></div></div><div class=\"inline_block four_col va_top show-overflow align_right\"><div class=\"fm-citation-ids\"><div class=\"fm-citation-pmcid\"><span class=\"fm-citation-ids-label\">PMCID: </span><span>PMC4069605</span></div><div class=\"fm-citation-manuscriptid\"><span class=\"fm-citation-ids-label\">NIHMSID: </span><span>NIHMS583147</span></div></div></div></div></div><h1 class=\"content-title\">EDTA Chelation Therapy Alone and in Combination with Oral High-Dose Multivitamins and Minerals for Coronary Disease: The Factorial Group Results of the Trial to Assess Chelation Therapy</h1><div class=\"half_rhythm\"><div class=\"contrib-group fm-author\"><a href=\"/pubmed/?term=Lamas%20GA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24952858\">Gervasio A. Lamas</a>, MD, <a href=\"/pubmed/?term=Boineau%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24952858\">Robin Boineau</a>, MD MA, <a href=\"/pubmed/?term=Goertz%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24952858\">Christine Goertz</a>, DC PhD, <a href=\"/pubmed/?term=Mark%20DB%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24952858\">Daniel B. Mark</a>, MD, MPH, <a href=\"/pubmed/?term=Rosenberg%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24952858\">Yves Rosenberg</a>, MD, <a href=\"/pubmed/?term=Stylianou%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24952858\">Mario Stylianou</a>, PhD, <a href=\"/pubmed/?term=Rozema%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24952858\">Theodore Rozema</a>, MD, <a href=\"/pubmed/?term=Nahin%20RL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24952858\">Richard L. Nahin</a>, PhD, MPH, <a href=\"/pubmed/?term=Chappell%20LT%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24952858\">L. Terry Chappell</a>, MD, <a href=\"/pubmed/?term=Lindblad%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24952858\">Lauren Lindblad</a>, MS, <a href=\"/pubmed/?term=Lewis%20EF%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24952858\">Eldrin F. Lewis</a>, MD, <a href=\"/pubmed/?term=Drisko%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24952858\">Jeanne Drisko</a>, MD, <a href=\"/pubmed/?term=Lee%20KL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24952858\">Kerry L. Lee</a>, PhD, and  the TACT Investigators</div></div><div class=\"fm-panel small half_rhythm\"><div class=\"fm-authors-info fm-panel hide half_rhythm\" id=\"id735391_ai\" style=\"display:none\"><div class=\"fm-affl\" lang=\"en\">The Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach FL (GAL); the National Heart, Lung, and Blood Institute, Bethesda MD (RB, YR, MS); The Palmer Center for Chiropractic Research, Davenport IA (CG); Biogenesis Medical Center, Landrum SC (TR); the National Center for Complementary and Alternative Medicine, Bethesda MD (RLN); Celebration of Health Association, Bluffton OH (LTC), Brigham and Women's Hospital and Harvard Medical School, Boston MA (EFL), The University of Kansas Medical Center, Kansas City, KS (JAD); and the Duke Clinical Research Institute (DBM, KLL, LL), Durham NC.</div><div id=\"CR1\">Editorial correspondence and reprint requests to Gervasio A. Lamas MD, Chief, Columbia University Division of Cardiology, Mount Sinai Medical Center, 4300 Alton Road Miami Beach FL 33140, 305.674.2260, 305.674.2169 (fax) or <span class=\"before-email-separator\">; </span><span class=\"email-label\">Email: </span><a href=\"mailto:dev@null\" data-email=\"moc.cmsm@samal.oisavreg\" class=\"oemail\">moc.cmsm@samal.oisavreg</a></div></div><div class=\"togglers\"><a href=\"#\" class=\"pmctoggle\" rid=\"id735391_ai\">Author information <span>\u25ba</span></a> <a href=\"#\" class=\"pmctoggle\" rid=\"id735391_cpl\">Copyright and License information <span>\u25ba</span></a></div><div class=\"fm-article-notes fm-panel half_rhythm\"></div><div class=\"fm-cpl-info fm-panel hide half_rhythm\" id=\"id735391_cpl\" style=\"display:none\"><div class=\"fm-copyright half_rhythm\"><a href=\"/pmc/about/copyright/\">Copyright notice</a>  and <a href=\"/About/disclaimer.html\">Disclaimer</a></div><div><a href=\"#FN1\">Publisher's Disclaimer</a></div></div></div><div id=\"pmclinksbox\" class=\"links-box fm-panel whole_rhythm\"><div class=\"small\"><div>The publisher's final edited version of this article is available  at <a href=\"/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=24952858\" target=\"pmc_ext\" ref=\"reftype=publisher&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access&amp;rendering-type=normal\">Am Heart J</a></div><div>See other articles in PMC that <a href=\"/pmc/articles/PMC4069605/citedby/\">cite</a> the published article.</div></div></div></div><div class=\"sec\"></div><div id=\"__abstractid1093573\" lang=\"en\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__abstractid1093573title\">Abstract</h2><!--article-meta--><div><div id=\"S1\" class=\"sec sec-first\"><h3>Background</h3><p id=\"P1\" class=\"p p-first-last\">Disodium ethylene diamine tetraacetic acid (EDTA) reduced adverse cardiac outcomes in a factorial trial also testing oral vitamins.</p></div><div id=\"S2\" class=\"sec\"><h3>Objective</h3><p id=\"P2\" class=\"p p-first-last\">This report describes the intent-to-treat comparison of the 4 factorial groups overall and in patients with diabetes.</p></div><div id=\"S3\" class=\"sec\"><h3>Methods</h3><p id=\"P3\" class=\"p p-first-last\">Double-blind placebo-controlled 2 &#x000d7; 2 factorial multicenter randomized trial of 1708 post-MI patients &#x02265; 50 years and creatinine &#x02264;2.0 mg/dL randomized to receive 40 EDTA chelation or placebo infusions plus 6 caplets daily of a 28-component multivitaminmultimineral mixture or placebo. Primary endpoint was a composite of total mortality, MI, stroke, coronary revascularization, or hospitalization for angina.</p></div><div id=\"S4\" class=\"sec\"><h3>Results</h3><p id=\"P4\" class=\"p p-first-last\">Median age was 65 years, 18% female, 94% Caucasian, 37% diabetic, 83% prior coronary revascularization, and 73% on statins. Five-year Kaplan-Meier estimates for the primary endpoint in the chelation + high-dose vitamin group was 31.9%, in the chelation + placebo vitamin group 33.7%, in the placebo infusion + active vitamin group 36.6%, and in the placebo infusions + placebo vitamin group 40.2 %. The reduction in primary endpoint by double active treatment compared with double placebo was significant (HR 0.74, 95% CI (0.57,0.95); p=0.016). In patients with diabetes, the primary endpoint reduction of double active compared with double placebo was more pronounced (HR 0.49, 95% CI (0.33,0.75), p&#x0003c;0.001).</p></div><div id=\"S5\" class=\"sec sec-last\"><h3>Conclusions</h3><p id=\"P5\" class=\"p p-first-last\">In stable post- MI patients on evidence-based medical therapy, the combination of oral high-dose vitamins and chelation therapy compared with double placebo reduced clinically important cardiovascular events to an extent that was both statistically significant and of potential clinical relevance.</p></div></div></div><div id=\"S6\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"S6title\">INTRODUCTION</h2><p id=\"P6\" class=\"p p-first\">Chelation therapy with ethylenediamine tetra acetic acid (EDTA) has long been used to treat atherosclerotic coronary and peripheral artery disease.<sup><strong><a href=\"#R1\" rid=\"R1\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981604\">1</a>,<a href=\"#R2\" rid=\"R2\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981614\">2</a></strong></sup> The Trial to Assess Chelation Therapy (TACT)<sup><strong><a href=\"#R3\" rid=\"R3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981603\">3</a></strong></sup> and found that this treatment reduced clinical events in post-myocardial infarction patients, particularly in patients with diabetes.<sup><strong><a href=\"#R4\" rid=\"R4\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_478484688\">4</a></strong></sup> Chelation therapy is often administered in conjunction with a regimen of oral high-dose vitamins and minerals,<sup><strong><a href=\"#R5\" rid=\"R5\" class=\" bibr popnode\">5</a></strong></sup> notwithstanding that he results of clinical trials of lower dose vitamin therapy have generally been negative.<sup><strong><a href=\"#R6\" rid=\"R6\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981600\">6</a>,<a href=\"#R7\" rid=\"R7\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981623\">7</a></strong></sup> Nonetheless, chelation practitioners argued forcefully during the design phase of TACT for the inclusion of an adjunctive high dose vitamin and mineral regimen. Thus, a 2 &#x000d7; 2 factorial design (intravenous chelation versus placebo plus oral vitamins versus placebo) was selected in order to control for the use of vitamins, study the effects of chelation with versus without high-dose vitamins and thereby eliminate potential confounding due to uncontrolled vitamin use by study participants.<sup><strong><a href=\"#R8\" rid=\"R8\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981601\">8</a></strong></sup></p><p id=\"P7\" class=\"p p-last\">The clinical safety and efficacy of the TACT vitamin regimen has been reported.<sup><strong><a href=\"#R9\" rid=\"R9\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_478484687\">9</a></strong></sup> These analyses demonstrated a non-significant, 11% reduction in the risk of the primary combined endpoint. The purpose of this paper is to describe the results across the 4 factorial groups in the 1708 randomized patients and among the 633 with diabetes.</p></div><div id=\"S7\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"S7title\">METHODS</h2><div id=\"S8\" class=\"sec sec-first\"><h3>Overview</h3><div id=\"P8\"><p>TACT, <a href=\"http://ClinicalTrials.gov\" ref=\"reftype=extlink&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal\" target=\"pmc_ext\">ClinicalTrials.gov</a> identifier <a id=\"__tag_561489722\" class=\"tag_hotlink\" href=\"https://clinicaltrials.gov/ct2/show/NCT00044213\" ref=\"reftype=extlink-ebi-arrayexpress&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials&amp;rendering-type=normal\"><span class=\"tag-json\" style=\"display:none\">{\"type\":\"clinical-trial\",\"attrs\":{\"text\":\"NCT00044213\",\"term_id\":\"NCT00044213\"}}</span>NCT00044213</a>, was a double-blind 2 &#x000d7; 2 factorial trial in which patients were randomized to four groups:\n</p><ol class=\"enumerated\" style=\"list-style-type:decimal\"><!--\nlist-behavior=enumerated\nprefix-word=\nmark-type=decimal\n--><li><div>Active IV chelation infusions + active oral vitamins</div></li><li><div>Active IV chelation infusions + placebo oral vitamins</div></li><li><div>Placebo IV chelation infusions + active oral vitamins</div></li><li><div>Placebo IV chelation infusions + placebo oral vitamins</div></li></ol><p> The design and organizational aspects of TACT have been published previously.<strong><sup><a href=\"#R8\" rid=\"R8\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981610\">8</a></sup></strong> The National Heart, Lung, and Blood Institute (NHLBI), grant # U01 HL92607 and the National Center for Complementary and Alternative Medicine (NCCAM), grant # U01AT001156 provided funding and oversight to support the research and creation of the paper. The institutional review board at each clinical site approved the study, and patients provided written informed consent. A Data and Safety Monitoring Board (DSMB) monitored the study. The authors are solely responsible for the design and conduct of the study, all study analyses, the drafting and editing of the paper and its final contents.</p></div></div><div id=\"S9\" class=\"sec\"><h3>Study population</h3><p id=\"P13\" class=\"p p-first-last\">Patients were at least 50 years of age and had sustained a myocardial infarction 6 weeks or more prior to enrollment. Patients were ineligible if they were women of childbearing potential, had a serum creatinine &#x0003e;2.0 mg/dL, or had other exclusion criteria as previously reported<sup><a href=\"#R8\" rid=\"R8\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981624\">8</a></sup>. Patients were enrolled at a total of 134 sites in the United States and Canada.</p></div><div id=\"S10\" class=\"sec\"><h3>Subgroup with diabetes</h3><p id=\"P14\" class=\"p p-first-last\">The study protocol called for examination of various pre-specified subgroups, diabetes among them. Therefore we also report exploratory analyses of the 4 factorial groups in patients with diabetes.</p></div><div id=\"S11\" class=\"sec\"><h3>Treatment</h3><p id=\"P15\" class=\"p p-first-last\">The contents of the preparation and administration of the EDTA and placebo EDTA infusion treatments used in TACT have been described<strong><sup><a href=\"#R8\" rid=\"R8\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981611\">8</a></sup></strong> (eTable1). Intravenous treatment consisted of 40 infusions of disodium EDTA-based chelation therapy or a normal saline placebo administered as 30 weekly infusions followed by 10 maintenance infusions 2 to 8 weeks apart. The active oral high-dose vitamin treatment was a 28-component mixture to be taken as 3 caplets twice daily until the end of follow-up. The components and dosing of the oral vitamins were developed with the assistance of chelation practitioners to reflect their standard practice (eTable 2).</p></div><div id=\"S12\" class=\"sec\"><h3>Follow-up</h3><p id=\"P16\" class=\"p p-first-last\">Patients were seen at baseline, and at each chelation infusion visit. Following the infusion phase, patients were called quarterly, attended annual clinic visits, and were seen at the end of the trial or at the 5 year follow-up, whichever was first. Vitamin/placebo caplets were distributed on a 3 to 6 monthly basis. Unused pills were returned to the site in order to assess compliance.</p></div><div id=\"S13\" class=\"sec\"><h3>Endpoints</h3><p id=\"P17\" class=\"p p-first-last\">The primary endpoint was a composite of death from any cause, reinfarction, stroke, coronary revascularization, or hospitalization for angina. The composite of cardiovascular death, reinfarction, or stroke was a prespecified key secondary endpoint. A blinded independent clinical events committee adjudicated all non-procedural components of the primary end-point. The data coordinating center (DCC) verified the occurrence of coronary revascularizations using patient medical records.</p></div><div id=\"S14\" class=\"sec\"><h3>Safety</h3><p id=\"P18\" class=\"p p-first-last\">Safety monitoring included periodic physical examination and laboratory assessments. A masked Medical Monitor at the DCC reviewed all serious adverse events.</p></div><div id=\"S15\" class=\"sec\"><h3>Pre-Specified Subgroups</h3><p id=\"P19\" class=\"p p-first-last\">TACT pre-specified several subgroups for analyses. The present report restricts itself to an analysis of the factorial groups in patients with diabetes prior to randomization, as previously defined.<strong><sup><a href=\"#R4\" rid=\"R4\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_478484683\">4</a></sup></strong></p></div><div id=\"S16\" class=\"sec sec-last\"><h3>Statistical analysis</h3><p id=\"P20\" class=\"p p-first\">As previously reported<strong><sup><a href=\"#R3\" rid=\"R3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981602\">3</a></sup></strong>, TACT enrolled 1708 patients, with a length of follow-up selected to provide 85% power for detecting a 25% relative reduction in the primary endpoint for each treatment factor, assuming a 2.5-year event rate in the placebo arm of 20% and a significance level of 0.05.</p><p id=\"P21\">The TACT statistical analysis plan pre-specified that the factorial groups would be analyzed for the overall study, in order to assess any interaction of chelation therapy with oral vitamins. The analyses of the 4 factorial groups in the diabetes subgroup was not pre-specified and, as such, should be considered an exploratory analysis.</p><p id=\"P22\" class=\"p p-last\">Randomization and treatment comparisons have been previously described. <strong><sup><a href=\"#R3\" rid=\"R3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981609\">3</a></sup></strong> The log-rank test<sup><strong><a href=\"#R10\" rid=\"R10\" class=\" bibr popnode\">10</a></strong></sup> was used for the statistical comparison of treatment groups. Cumulative event rates were calculated according to the Kaplan-Meier method. <sup><strong><a href=\"#R11\" rid=\"R11\" class=\" bibr popnode\">11</a></strong></sup> Relative risks were expressed as hazard ratios (HR) with associated confidence intervals (CI), and were calculated using the Cox proportional hazards model.<sup><strong><a href=\"#R12\" rid=\"R12\" class=\" bibr popnode\">12</a></strong></sup> Outcomes were compared across the factorial groups, both in the overall population as well as for the population of patients with diabetes. Comparisons of treatment groups with respect to adherence and safety were performed using the chi-square test. Continuous variables are expressed as medians and interquartile ranges (IQRs) unless otherwise specified. Statistical analyses were performed using SAS software, versions 8.2 and 9.2 (SAS Institute, Cary NC).</p></div></div><div id=\"S17\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"S17title\">RESULTS</h2><p id=\"P23\" class=\"p p-first\">Between September 10, 2003 and October 4, 2010, 1708 patients were randomized, 421 to EDTA chelation infusions+ high dose oral multivitamins, 418 to EDTA chelation infusions+ oral placebo, 432 to placebo infusions + high-dose oral multivitamins, and 437 to placebo infusions + oral placebo. The median duration of follow-up was 55 months (IQR 26,60) overall. There was no significant difference in length of follow-up across all 4 groups.</p><div id=\"S18\" class=\"sec\"><h3>Baseline characteristics</h3><p id=\"P24\" class=\"p p-first-last\">Baseline characteristics were similar among the 4 randomized factorial groups (<a href=\"/pmc/articles/PMC4069605/table/T1/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"T1\" rid-ob=\"ob-T1\" co-legend-rid=\"\"><span>Table 1</span></a>). Patients were 65 (59,72) years old, 18% female, and 9% minority. The qualifying myocardial infarction had occurred 4.6 (1.6, 9.2) years prior to enrollment. There was a high prevalence of diabetes (37%), of prior coronary revascularizations (83%), and post-infarct, guideline-recommended medication use of aspirin (84%), beta-blocker (72%), and statin (73%).</p><!--table ft1--><!--table-wrap mode=article t1--><div class=\"table-wrap iconblock ten_col whole_rhythm clearfix\" id=\"T1\"><a href=\"/pmc/articles/PMC4069605/table/T1/\" target=\"table\" rid-ob=\"ob-T1\" rid-figpopup=\"T1\" class=\"table img_link icnblk_img figpopup\"><img alt=\"Table 1\" title=\"Table 1\" class=\"small-thumb\" src=\"/pmc/articles/PMC4069605/table/T1/?report=thumb\" src-large=\"/pmc/articles/PMC4069605/table/T1/?report=previmg\" /></a><div class=\"icnblk_cntnt\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4069605/table/T1/\" target=\"table\" rid-figpopup=\"T1\" rid-ob=\"ob-T1\">Table 1</a></div><!--caption a4--><div><span>Baseline Characteristics of Patients for All 4 Factorial Groups</span></div></div></div></div><div id=\"S19\" class=\"sec\"><h3>Factorial Treatment Comparisons (overall group)</h3><p id=\"P25\" class=\"p p-first\">The 5-year Kaplan-Meier event rate estimate for the primary endpoint in the chelation + high-dose vitamin group was 31.9%, in the chelation + placebo vitamin group 33.7%, in the placebo infusion + active vitamin group 36.6%, and in the placebo infusions + placebo vitamin group 40.2 % (<a href=\"/pmc/articles/PMC4069605/figure/F1/\" target=\"figure\" class=\"fig-table-link fig figpopup\" rid-figpopup=\"F1\" rid-ob=\"ob-F1\" co-legend-rid=\"lgnd_F1\"><span>Figure 1a</span></a>, <a href=\"/pmc/articles/PMC4069605/table/T2/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"T2\" rid-ob=\"ob-T2\" co-legend-rid=\"\"><span>Table 2</span></a>,). The primary endpoint by treatment group occurred in 139 (32%) of the placebo infusion + placebo vitamin group, and 108 (26%) of patients in the chelation + high-dose vitamin group (<a href=\"/pmc/articles/PMC4069605/figure/F2/\" target=\"figure\" class=\"fig-table-link fig figpopup\" rid-figpopup=\"F2\" rid-ob=\"ob-F2\" co-legend-rid=\"lgnd_F2\"><span>Figure 1b</span></a>). The groups with one active therapy had an intermediate number of events and were not statistically significantly different from the placebo-placebo group. The comparison of active infusion + active vitamins with placebo infusions + placebo vitamins was significant (HR 0.74, 95% CI (0.57,0.95); p=0.016). The absolute difference in 5-year Kaplan-Meier estimated event rates between placebo-placebo and active-active groups was 8.3% and the number needed to treat (NNT) to prevent 1 event over 5 years was 12.</p><!--fig ft0--><!--fig mode=article f1--><div class=\"fig iconblock ten_col whole_rhythm clearfix\" id=\"F1\" co-legend-rid=\"lgnd_F1\"><a class=\"icnblk_img figpopup\" href=\"/pmc/articles/PMC4069605/figure/F1/\" target=\"figure\" rid-figpopup=\"F1\" rid-ob=\"ob-F1\"><img src=\"/pmc/articles/PMC4069605/bin/nihms-583147-f0001.gif\" class=\"small-thumb\" alt=\"Figure 1a\" title=\"Figure 1a\" src-large=\"/pmc/articles/PMC4069605/bin/nihms-583147-f0001.jpg\" /></a><div class=\"icnblk_cntnt\" id=\"lgnd_F1\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4069605/figure/F1/\" target=\"figure\" rid-figpopup=\"F1\" rid-ob=\"ob-F1\">Figure 1a</a></div><!--caption a4--><div><span>Kaplan-Meler curves(4 groups, 1<sup>0</sup> endpoint, factorial)</span></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class=\"fig iconblock ten_col whole_rhythm clearfix\" id=\"F2\" co-legend-rid=\"lgnd_F2\"><a class=\"icnblk_img figpopup\" href=\"/pmc/articles/PMC4069605/figure/F2/\" target=\"figure\" rid-figpopup=\"F2\" rid-ob=\"ob-F2\"><img src=\"/pmc/articles/PMC4069605/bin/nihms-583147-f0002.gif\" class=\"small-thumb\" alt=\"Figure 1b\" title=\"Figure 1b\" src-large=\"/pmc/articles/PMC4069605/bin/nihms-583147-f0002.jpg\" /></a><div class=\"icnblk_cntnt\" id=\"lgnd_F2\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4069605/figure/F2/\" target=\"figure\" rid-figpopup=\"F2\" rid-ob=\"ob-F2\">Figure 1b</a></div><!--caption a4--><div><span>Kaplan-Meier curves placebo/placebo vs. active/active (1<sup>0</sup> endpont, factorial)</span></div></div></div><!--table ft1--><!--table-wrap mode=article t1--><div class=\"table-wrap iconblock ten_col whole_rhythm clearfix\" id=\"T2\"><a href=\"/pmc/articles/PMC4069605/table/T2/\" target=\"table\" rid-ob=\"ob-T2\" rid-figpopup=\"T2\" class=\"table img_link icnblk_img figpopup\"><img alt=\"Table 2\" title=\"Table 2\" class=\"small-thumb\" src=\"/pmc/articles/PMC4069605/table/T2/?report=thumb\" src-large=\"/pmc/articles/PMC4069605/table/T2/?report=previmg\" /></a><div class=\"icnblk_cntnt\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4069605/table/T2/\" target=\"table\" rid-figpopup=\"T2\" rid-ob=\"ob-T2\">Table 2</a></div><!--caption a4--><div><span>Primary and Secondary Endpoint Components for all Four Factorial Groups</span></div></div></div><p id=\"P26\" class=\"p p-last\">The principal secondary endpoint, cardiovascular death, MI, or stroke occurred in 58 (13%) of the placebo infusions + placebo vitamin group, 57 (14%) of the chelation + placebo vitamin group, 55 (13%) of the placebo infusion + active vitamin group, and 39 (9%) of patients in the chelation + high-dose vitamin group. The comparison of active infusion + active vitamins with placebo infusions + placebo vitamins favored chelation + vitamins (HR 0.66, 95% CI 0.44,0.99, p=0.046). The groups with one active therapy had an intermediate number of events, and were not statistically significantly different from the placebo-placebo group.</p></div><div id=\"S20\" class=\"sec\"><h3>Treatment adherence</h3><p id=\"P27\" class=\"p p-first-last\">There were no significant differences in adherence to IV infusions or to oral vitamins between groups (<a href=\"/pmc/articles/PMC4069605/table/T3/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"T3\" rid-ob=\"ob-T3\" co-legend-rid=\"\"><span>Table 3</span></a>). Consent withdrawal at some point during the trial was reported in 289 patients. A greater frequency of consent withdrawals occurred among patients randomized to placebo infusions.</p><!--table ft1--><!--table-wrap mode=article t1--><div class=\"table-wrap iconblock ten_col whole_rhythm clearfix\" id=\"T3\"><a href=\"/pmc/articles/PMC4069605/table/T3/\" target=\"table\" rid-ob=\"ob-T3\" rid-figpopup=\"T3\" class=\"table img_link icnblk_img figpopup\"><img alt=\"Table 3\" title=\"Table 3\" class=\"small-thumb\" src=\"/pmc/articles/PMC4069605/table/T3/?report=thumb\" src-large=\"/pmc/articles/PMC4069605/table/T3/?report=previmg\" /></a><div class=\"icnblk_cntnt\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4069605/table/T3/\" target=\"table\" rid-figpopup=\"T3\" rid-ob=\"ob-T3\">Table 3</a></div><!--caption a4--><div><span>Patient Status by all Treatment Arms</span></div></div></div></div><div id=\"S21\" class=\"sec\"><h3>Safety</h3><p id=\"P28\" class=\"p p-first-last\">Serious adverse events were documented in 55 patients (13%) of the EDTA chelation and high-dose vitamin group, 45 (11%) of the EDTA chelation and placebo vitamin group, 69 (16%) of the placebo infusion and high-dose vitamin group, and 58 (13%) of the placebo infusion and placebo vitamin group (p= 0.170).</p></div><div id=\"S22\" class=\"sec sec-last\"><h3>Diabetes analyses</h3><p id=\"P29\" class=\"p p-first-last\">In the 633 patients with diabetes, the 5-year Kaplan-Meier event rate estimates for the primary endpoint in the chelation + high-dose vitamin group was 29.1%, in the chelation + placebo vitamin group 36.1%, in the placebo infusion + active vitamin group 48.1%, and in the placebo infusions + placebo vitamin group 47.3% (<a href=\"/pmc/articles/PMC4069605/figure/F3/\" target=\"figure\" class=\"fig-table-link fig figpopup\" rid-figpopup=\"F3\" rid-ob=\"ob-F3\" co-legend-rid=\"lgnd_F3\"><span>Figure2a</span></a>). The primary endpoint by treatment group occurred in 56 (38%) of the placebo infusion + placebo vitamin group, and 36 (23%) of patients in the chelation + high-dose vitamin group (HR 0.49, 95% CI (0.33,0.75) p&#x0003c;0.001, 5-year NNT=5.5, <a href=\"/pmc/articles/PMC4069605/figure/F4/\" target=\"figure\" class=\"fig-table-link fig figpopup\" rid-figpopup=\"F4\" rid-ob=\"ob-F4\" co-legend-rid=\"lgnd_F4\"><span>Figure 2b</span></a>). The factorial groups receiving only one active treatment had intermediate treatment benefit, not statistically significantly different from double placebo.</p><!--fig ft0--><!--fig mode=article f1--><div class=\"fig iconblock ten_col whole_rhythm clearfix\" id=\"F3\" co-legend-rid=\"lgnd_F3\"><a class=\"icnblk_img figpopup\" href=\"/pmc/articles/PMC4069605/figure/F3/\" target=\"figure\" rid-figpopup=\"F3\" rid-ob=\"ob-F3\"><img src=\"/pmc/articles/PMC4069605/bin/nihms-583147-f0003.gif\" class=\"small-thumb\" alt=\"Figure 2a\" title=\"Figure 2a\" src-large=\"/pmc/articles/PMC4069605/bin/nihms-583147-f0003.jpg\" /></a><div class=\"icnblk_cntnt\" id=\"lgnd_F3\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4069605/figure/F3/\" target=\"figure\" rid-figpopup=\"F3\" rid-ob=\"ob-F3\">Figure 2a</a></div><!--caption a4--><div><span>Kaplan-Meier curves(4groups, 1<sup>0</sup> endpoint, diabetes)</span></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class=\"fig iconblock ten_col whole_rhythm clearfix\" id=\"F4\" co-legend-rid=\"lgnd_F4\"><a class=\"icnblk_img figpopup\" href=\"/pmc/articles/PMC4069605/figure/F4/\" target=\"figure\" rid-figpopup=\"F4\" rid-ob=\"ob-F4\"><img src=\"/pmc/articles/PMC4069605/bin/nihms-583147-f0004.gif\" class=\"small-thumb\" alt=\"Figure 2b\" title=\"Figure 2b\" src-large=\"/pmc/articles/PMC4069605/bin/nihms-583147-f0004.jpg\" /></a><div class=\"icnblk_cntnt\" id=\"lgnd_F4\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4069605/figure/F4/\" target=\"figure\" rid-figpopup=\"F4\" rid-ob=\"ob-F4\">Figure 2b</a></div><!--caption a4--><div><span>Kaplan-Meier curves placebo/placebo vs. active/active(1<sup>0</sup> endpoint, diabetes)</span></div></div></div></div></div><div id=\"S23\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"S23title\">DISCUSSION</h2><p id=\"P30\" class=\"p p-first\">TACT was designed as a factorial trial of intravenous EDTA-based chelation and high-dose oral vitamins, to reflect chelation practice in the community, and control for confounding. Thus, we pre-specified an analysis of the 4 groups of the factorial treatment allocation. The analyses demonstrated a stepwise gradient in benefit, with highest risk accrued by patients on standard post-MI care, but neither chelation nor vitamins; intermediate risk by patients receiving only one intervention; and lowest risk by patients receiving both chelation and vitamins. When compared with patients receiving placebo only, the hazard ratio of patients receiving both the study interventions was 0.74 (95%CI 0.57, 0.95, p=0.016), with the 5-year NNT for the primary endpoint of 12. This compares with the 5-year NNT of 16 for statin therapy for secondary prevention.<sup><strong><a href=\"#R13\" rid=\"R13\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981615\">13</a></strong></sup> These effects were observed against a background of modern, evidence-based treatments for post-MI patients, including statins in 73% of patients, with a median LDL cholesterol of 89 mg/dL. Moreover, the benefit of combined therapy in patients with diabetes was greater, with a 5-year NNT for the primary endpoint of 5.5, again with a background of statin therapy in 76% of the diabetic patients.</p><p id=\"P31\">Others have reported epidemiological<sup><strong><a href=\"#R14\" rid=\"R14\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_478484684\">14</a>,<a href=\"#R15\" rid=\"R15\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981607\">15</a>,<a href=\"#R16\" rid=\"R16\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981616\">16</a></strong></sup> and experimental findings <sup><strong><a href=\"#R17\" rid=\"R17\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981619\">17</a></strong></sup>\n<sup><strong><a href=\"#R18\" rid=\"R18\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981626\">18</a></strong></sup>\n<sup><strong><a href=\"#R19\" rid=\"R19\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981606\">19</a></strong></sup> that may explain benefits of metal chelation in cardiovascular disease. Lead and cadmium are associated with myocardial infarction, stroke, hypertension, and death. Mechanisms include individual toxicities for each metal ion, but also a class-specific action on the body's defenses against oxidant stress. EDTA chelates environmental contaminants like lead, cadmium, antimony, tungsten, and many others<sup><strong><a href=\"#R20\" rid=\"R20\" class=\" bibr popnode\">20</a></strong></sup>. In diabetic patients, copper and iron, both chelated by EDTA, are tightly linked to non-enzymatic catalytic oxidation of glucose, leading to the formation of advanced glycation end products. Other metals,<sup><strong><a href=\"#R21\" rid=\"R21\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981613\">21</a></strong></sup> also chelated by EDTA, may be involved with these redox reactions in diabetic patients, accounting for yet another mechanism of action for EDTA. The xenobiotic metal hypothesis is particularly appealing because the clinical benefits of chelation persist even after the infusions stop, with continued late separation of event curves.</p><p id=\"P32\">There are other potential explanations for the observed treatment effect. The chelation solution contains a high dose of vitamin C, an antioxidant vitamin that may help reverse some forms of endothelial dysfunction.<sup><strong><a href=\"#R22\" rid=\"R22\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981622\">22</a></strong></sup> Whether repetitive infusions of vitamin C could lead to the persistent effect observed in TACT after infusions stop, however, seems doubtful.</p><p id=\"P33\">Vitamin therapy has been exhaustively studied in clinical trials as primary prevention for coronary disease. Those trials, which have largely failed to detect any evidence of a treatment benefit, have almost all used one or a small numbers of single vitamins at modest doses.<sup><strong><a href=\"#R7\" rid=\"R7\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981612\">7</a>,<a href=\"#R23\" rid=\"R23\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981628\">23</a></strong></sup> Thus, the lack of benefit of oral vitamins and minerals on cardiovascular events in prior studies should be recognized as pertaining to a different regimen than the high dose oral multivitamin and mineral regimen used here and a different (primary versus secondary prevention) study population.</p><p id=\"P34\" class=\"p\">The incremental benefit observed in the vitamin + chelation group calls for a methodological explanation. We reported that there was a non-significant, 11% reduction in the point estimate of the primary endpoint with oral vitamin therapy<sup><strong><a href=\"#R9\" rid=\"R9\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_478484685\">9</a></strong></sup> Our trial was not powered to detect an 11% difference between groups with sufficient precision to exclude the null effect. This small benefit of oral vitamin therapy, although not statistically significant by itself, may explain the incremental reduction in hazard ratio, from 0.82<sup><a href=\"#R3\" rid=\"R3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981605\">3</a></sup> to 0.74, we observed when patients receiving both active treatments were compared to the double placebo patients. A similar explanation applies to the large benefit observed in patients with diabetes treated with the double active regimen, compared with the double placebo.</p><div id=\"S24\" class=\"sec\"><h3>Study caveats</h3><p id=\"P35\" class=\"p p-first\">Given the unexpected findings of TACT for practitioners of cardiovascular medicine, establishing the clinical and scientific significance of the TACT findings will require the performance of additional (i.e., more than one) high quality, adequately powered clinical trials, along with relevant laboratory studies to help identify mechanisms of benefit.</p><p id=\"P36\" class=\"p p-last\">Noncompliance with randomized treatment likely reduced the power of the study to discern a difference between groups. The compliance issues have been reviewed in detail in prior publications, and the significance of chelation therapy benefit was maintained in conservative sensitivity analyses<sup><strong><a href=\"#R3\" rid=\"R3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_384981618\">3</a>,<a href=\"#R4\" rid=\"R4\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_478484686\">4</a></strong></sup> In addition, all patients had their death index status checked at the end of the study, and some patients withdrew after having sustained a primary endpoint, which mitigates some loss of data.</p></div><div id=\"S25\" class=\"sec\"><h3>Conclusions</h3><p id=\"P37\" class=\"p p-first-last\">In stable post- MI patients on evidence-based medical therapy, the combination of oral high-dose vitamins and chelation therapy compared with double placebo reduced clinically important cardiovascular events to an extent that was both statistically significant and of potential clinical relevance.</p></div><div id=\"S26\" class=\"sec sec-last\"><h3>Disclaimer</h3><p id=\"P38\" class=\"p p-first-last\">The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Heart, Lung, and Blood Institute, the National Center for Complementary and Alternative Medicine, or the National Institutes of Health.</p></div></div><div id=\"S27\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"S27title\">Acknowledgements</h2><div class=\"sec\"><p id=\"__p1\">The authors gratefully acknowledge the organizational skills of Ana Mon MPH Project Leader at the Clinical Coordinating Center, Alyssa Cotler at NCCAM, Susan Dambrauskas (formerly at NHLBI), and Vivian Thompson at the DCRI for their competent professional assistance, and the Florida Heart Research Institute for supporting the pilot study. Gervasio Lamas MD reports that from 2000 to 2003 he served as a consultant to OmniComm, the electronic data capture company used in the trial. No funds were received, and all ties were severed as of 09/10/2003. The authors have no other conflicts to report.</p></div></div><div id=\"__fn-groupid734249\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__fn-groupid734249title\">Footnotes</h2><!--back/fn-group--><div class=\"fm-sec half_rhythm small\"><p class=\"fn sec\" id=\"FN1\"><p id=\"P39\" class=\"p p-first-last\"><strong>Publisher's Disclaimer: </strong>This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.</p></p></div></div><div id=\"__ref-listid1188247\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__ref-listid1188247title\">References</h2><div class=\"ref-list-sec sec\" id=\"reference-list\"><div class=\"ref-cit-blk half_rhythm\" id=\"R1\">1. <span class=\"element-citation\">Clarke NE, Clarke CN, Mosher RE. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. <span><span class=\"ref-journal\">Am J Med Sci. </span>1956;<span class=\"ref-vol\">232</span>(6):654\u2013666.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/13372537\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R2\">2. <span class=\"element-citation\">Grier MT, Meyers DG. So much writing, so little science: A review of 37 years of literature on Edetate Sodium chelation therapy. <span><span class=\"ref-journal\">Ann Pharmacother. </span>1993;<span class=\"ref-vol\">27</span>:1504\u20131509.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/8305786\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R3\">3. <span class=\"element-citation\">Lamas GA, Goertz C, Boineau R. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. <span><span class=\"ref-journal\">JAMA. </span>2013 Mar 27;<span class=\"ref-vol\">309</span>(12):1241\u201350.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC4066975/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/23532240\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R4\">4. <span class=\"element-citation\">Escolar E, Lamas GA, Mark DB. The Effect of an EDTA-based Chelation Regimen on Patients With Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT). <span><span class=\"ref-journal\">Circ Cardiovasc Qual Outcomes. </span>2014;<span class=\"ref-vol\">7</span>:15\u201324.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC4111470/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/24254885\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R5\">5. <span class=\"element-citation\">Rozema TC. Special issue: protocols for chelation therapy. <span><span class=\"ref-journal\">J Adv Med. </span><span class=\"ref-vol\">10</span>:5\u2013100.</span> 997.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R6\">6. <span class=\"element-citation\">Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysis. <span><span class=\"ref-journal\">J Am Med Assoc. </span>2007;<span class=\"ref-vol\">297</span>(8):842\u2013857.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/17327526\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R7\">7. <span class=\"element-citation\">Sasso HD, Christen WG, Bubes V, et al.  Multivitamins in the prevention of cardiovascular disease in men: the Physicians&#x02019; Health Study II randomized controlled trial. <span><span class=\"ref-journal\">JAMA. </span><span class=\"ref-journal\">Nov 7. </span>2012;<span class=\"ref-vol\">308</span>(17):1751\u201360.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC3501249/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/23117775\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R8\">8. <span class=\"element-citation\">Lamas GA, Goertz C, Boineau R, et al.  Design of the trial to assess chelation therapy (TACT). <span><span class=\"ref-journal\">Am Heart J. </span>2012;<span class=\"ref-vol\">163</span>(1):7\u201312.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC3243954/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/22172430\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R9\">9. <span class=\"element-citation\">Lamas G, Boineau R, Goertz C, et al.  Oral High-Dose Multivitamins and Minerals After Myocardial Infarction. A Randomized, Controlled Trial. <span><span class=\"ref-journal\">Ann Intern Med. </span>2013;<span class=\"ref-vol\">159</span>:797\u2013804.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC4143134/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/24490264\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R10\">10. <span class=\"element-citation\">Kalbfleisch JD, Prentice RL.  <span class=\"ref-journal\">The Statistical Analysis of Failure Time Data.</span> Second Edition John Wiley &#x00026; Sons, Inc; New York: 2002. </span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R11\">11. <span class=\"element-citation\">Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. <span><span class=\"ref-journal\">J Am Statist Assn. </span>1958;<span class=\"ref-vol\">53</span>:457\u2013481.</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R12\">12. <span class=\"element-citation\">Cox DR. Regression models and life-tables (with discussion). <span><span class=\"ref-journal\">J Royal Statist Soc B. </span>1972;<span class=\"ref-vol\">34</span>:187\u2013220.</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R13\">13. <span class=\"element-citation\">Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. <span><span class=\"ref-journal\">BMJ. </span>2006;<span class=\"ref-vol\">332</span>:1115\u201324.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC1459619/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16585050\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R14\">14. <span class=\"element-citation\">Tellez-Plaza M, Guallar E, Fabsitz RR, et al.  Cadmium exposure and incident peripheral arterial disease. <span><span class=\"ref-journal\">Circ Cardiovasc Qual Outcomes. </span>2013;<span class=\"ref-vol\">6</span>:626\u201333.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC4190067/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/24255048\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R15\">15. <span class=\"element-citation\">Menke A, Muntner P, Batuman VV, Silbergeld EK, Guallar E. Blood lead below 0.48 &#x003bc;mol/L (10 &#x003bc;g/dL) and mortality among US adults. <span><span class=\"ref-journal\">Circulation. </span>2006;<span class=\"ref-vol\">114</span>(13):1388\u20131394.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16982939\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R16\">16. <span class=\"element-citation\">Nawrot TS, Staessen JA. Low-level environmental exposure to lead unmasked as silent killer. <span><span class=\"ref-journal\">Circulation. </span>2006;<span class=\"ref-vol\">114</span>:1347\u20139.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/17000919\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R17\">17. <span class=\"element-citation\">Monnier VM. Transition metals redox: reviving an old plot for diabetic vascular disease. <span><span class=\"ref-journal\">J Clin Invest. </span>2001;<span class=\"ref-vol\">107</span>:799\u2013801.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC199584/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/11285298\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R18\">18. <span class=\"element-citation\">Nagai R, Murray DB, Metz TO, et al.  Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. <span><span class=\"ref-journal\">Diabetes. </span>2012;<span class=\"ref-vol\">61</span>:549\u201359.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC3282805/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/22354928\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R19\">19. <span class=\"element-citation\">Frizzell N, Baynes JW. Chelation therapy: overlooked in the treatment and prevention of diabetes complications? <span><span class=\"ref-journal\">Future Med Chem. </span>2013;<span class=\"ref-vol\">5</span>:1075\u20138.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/23795964\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R20\">20. <span class=\"element-citation\">Cranton EM, Liu ZX, Smith IM.  <span class=\"ref-journal\">Urinary Trace and Toxic Elements and Minerals in Untimed Urine Specimens. In Textbook on EDTA Chelation Therapy.</span> 2nd Ed. Hampton Roads Publishing Co; Charlottesville, VA: 2001. pp. 503\u2013539.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R21\">21. <span class=\"element-citation\">Agarwal S, Zaman T, Tuzcu EM, Kapadia SR. Heavy metals and cardiovascular disease: results from the National Health and Nutrition Examination Survey (NHANES) 1999-2006. <span><span class=\"ref-journal\">Angiology. </span>2011;<span class=\"ref-vol\">62</span>(5):422\u2013429.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/21421632\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R22\">22. <span class=\"element-citation\">Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Jr, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. <span><span class=\"ref-journal\">Circulation. </span>1996;<span class=\"ref-vol\">93</span>(6):1107\u20131113.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/8653830\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R23\">23. <span class=\"element-citation\">Bailey RL, Gahche JJ, Lentino CV, Dwyer JT, Engel JS, Thomas PR, et al.  Dietary supplement use in the United States, 2003-2006. <span><span class=\"ref-journal\">J Nutr. </span>2011;<span class=\"ref-vol\">141</span>:261\u20136.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC3021445/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/21178089\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4069605&amp;issue-id=239372&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div></div></div></div><!--post-content--></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id=\"rightcolumn\" class=\"four_col col last\">\n        <!-- Custom content above discovery portlets -->\n        <div class=\"col6\">\n            \n        </div>\n        \n        <div xmlns:np=\"http://ncbi.gov/portal/XSLT/namespace\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\"><div class=\"format-menu\"><h2>Formats:</h2><ul><li class=\"selected\">Article</li> | <li><a href=\"/pmc/articles/PMC4069605/?report=reader\">PubReader</a></li> | <li class=\"epub-link\"><a href=\"/pmc/articles/PMC4069605/epub/\">ePub (beta)</a></li> | <li><a href=\"/pmc/articles/PMC4069605/pdf/nihms-583147.pdf\">PDF (686K)</a></li> | <li><a href=\"#\" data-citationid=\"PMC4069605\" class=\"citationexporter ctxp\">Citation</a></li></ul></div></div><div xmlns:np=\"http://ncbi.gov/portal/XSLT/namespace\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" class=\"share-buttons\"><h2>Share</h2><ul><li class=\"facebook\"><a href=\"https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4069605%2F\"><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/4047626\" alt=\"Share on Facebook\" />\n                             Facebook\n                        </a></li><li class=\"twitter\"><a href=\"https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4069605%2F&amp;text=EDTA%20Chelation%20Therapy%20Alone%20and%20in%20Combination%20with%20Oral%20High-Dose%20Multivitamins%20and%20Minerals%20for%20Coronary%20Disease%3A%20The%20Factorial%20Group%20Results%20of%20the%20Trial%20to%20Assess%20Chelation%20Therapy\"><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/4047627\" alt=\"Share on Twitter\" />\n                             Twitter\n                        </a></li><li class=\"gplus\"><a href=\"https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4069605%2F\"><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/4047628\" alt=\"Share on Google Plus\" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id=\"ajax-portlets\" data-pmid=\"24952858\" data-aiid=\"4069605\" data-aid=\"4069605\" data-iid=\"239372\" data-domainid=\"319\" data-domain=\"nihpa\" data-accid=\"PMC4069605\" data-md5=\"a30b51c71b69d3ac0a608459dcf21c02\"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class=\"col7\">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class=\"col8\">\n    \n</div>\n<div class=\"col9\">\n    \n</div>\n\n<script src=\"/corehtml/pmc/js/jquery.scrollTo-1.4.2.js\"></script>\n<script>\n    (function($){\n        $('.skiplink').each(function(i, item){\n            var href = $($(item).attr('href'));\n            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus\n            $(item).on('click', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id=\"body-link-poppers\"></div>\n                        </div>\n                        <div class=\"bottom\">\n                            \n                            <div id=\"NCBIFooter_dynamic\">\n    <div class=\"breadcrumbs\">You are here: \n            <span id=\"breadcrumb_text\"><a href=\"/guide/\">NCBI</a> &gt; <a href=\"https://www.ncbi.nlm.nih.gov/guide/literature/\">Literature</a> &gt; <a href=\"https://www.ncbi.nlm.nih.gov/pmc/\">PubMed Central (PMC)</a></span></div>\n    <a id=\"help-desk-link\" class=\"help_desk jig-ncbihelpwindow\" target=\"_blank\" href=\"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.39&amp;Time=2016-11-05T22:45:34-04:00&amp;Host=ptpmc202\">Write to the Help Desk</a>\n    \n</div>\n\n                            <div class=\"footer\" id=\"footer\">\n    \n    <div class=\"subfooter\"> </div><script type=\"text/javascript\" src=\"/portal/portal3rc.fcgi/static/js/preloaderWidget.js\"> </script>\n    <div id=\"external-disclaimer\" class=\"offscreen_noflow\">\n        External link. Please review our <a href=\"https://www.nlm.nih.gov/privacy.html\">privacy policy</a>.\n    </div>    \n    <div id=\"ncbifooter\" class=\"contact_info\">      \n        <div id=\"footer-contents-right\">\n            <div id=\"nlm_thumb_logo\">\n                <a href=\"https://www.nlm.nih.gov\" title=\"NLM\">NLM</a>\n            </div>\n            <div id=\"nih_thumb_logo\">\n                <a href=\"https://www.nih.gov\" title=\"NIH\">NIH</a>\n            </div>\n            <div id=\"hhs_thumb_logo\">\n                <a href=\"https://www.hhs.gov\" title=\"DHHS\">DHHS</a>\n            </div>\n            <div id=\"usagov_thumb_logo\">\n                <a href=\"https://www.usa.gov\" title=\"USA.gov\">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id=\"footer-contents-left\">\n            <p class=\"address vcard\">\n                <span class=\"url\">\n                    <a class=\"fn url newdomain\" href=\"https://www.ncbi.nlm.nih.gov\">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class=\"org url newdomain\"><a href=\"https://www.nlm.nih.gov/\">U.S. National Library of Medicine</a></span>\n                <span class=\"adr\">\n                    <span class=\"street-address\">8600 Rockville Pike</span>, <span class=\"locality\">Bethesda</span>\n                    <span class=\"region\">MD</span>, <span class=\"postal-code\">20894</span>\n                    <span class=\"country-name\">USA</span>\n                </span>\n            </p>\n            \n            <a href=\"/home/about/policies.shtml\">Policies and Guidelines</a> | <a href=\"/home/about/contact.shtml\">Contact</a>\n        </div>\n    </div>\n    <script type=\"text/javascript\" src=\"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1\"> </script>    \n    <script type=\"text/javascript\" src=\"/portal/portal3rc.fcgi/static/js/hfjs2.js\"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class=\"PAFAppResources\"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt=\"statistics\" src=\"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=nihpa&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC4069605/&amp;ncbi_app=pmc\" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id=\"PageFixtures\" label=\"styles\"></component>-->\n    \n\n<!-- F4FC57FD81E994D1_0067SID /projects/PMC/PMCViewer@4.39 ptpmc202 v4.1.r508797 Mon, Aug 01 2016 12:51:16 -->\n\n<script type=\"text/javascript\" src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/js/3879255/4121861/3818874/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js\" snapshot=\"pmc\"></script></body>\n</html>"}